HighMark Wealth Management LLC Increases Stake in AtriCure, Inc. (NASDAQ:ATRC)

HighMark Wealth Management LLC raised its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 19.2% during the fourth quarter, HoldingsChannel reports. The firm owned 83,725 shares of the medical device company’s stock after purchasing an additional 13,500 shares during the quarter. AtriCure makes up about 1.5% of HighMark Wealth Management LLC’s investment portfolio, making the stock its 12th largest position. HighMark Wealth Management LLC’s holdings in AtriCure were worth $2,559,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arcadia Investment Management Corp MI purchased a new stake in AtriCure during the 3rd quarter valued at about $28,000. Heck Capital Advisors LLC purchased a new stake in AtriCure in the fourth quarter valued at approximately $60,000. Venturi Wealth Management LLC increased its holdings in AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after buying an additional 2,100 shares during the period. KBC Group NV raised its position in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after buying an additional 932 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in AtriCure during the 4th quarter valued at approximately $89,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ATRC. JMP Securities reissued a “market outperform” rating and set a $60.00 target price on shares of AtriCure in a report on Monday, February 10th. Needham & Company LLC reiterated a “buy” rating and set a $51.00 price objective on shares of AtriCure in a research note on Thursday, February 13th. JPMorgan Chase & Co. upped their target price on AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Stifel Nicolaus raised their target price on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Oppenheimer boosted their price target on AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Stock Up 3.4 %

AtriCure stock opened at $40.94 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. The stock has a market capitalization of $2.00 billion, a PE ratio of -49.33 and a beta of 1.46. The business has a 50 day simple moving average of $35.90 and a 200-day simple moving average of $31.64. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.